Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations
Targeted protein degradation (TPD) is a promising strategy for drug development. In this proof-of-concept study, the authors use telaprevir, which binds hepatitis C virus (HCV) NS3/4A protease, to target the protease for protein degradation, and show inhibition of wildtype as well as drug resistant...
Full description
Bibliographic Details
| Main Authors: |
Mélissanne de Wispelaere,
Guangyan Du,
Katherine A. Donovan,
Tinghu Zhang,
Nicholas A. Eleuteri,
Jingting C. Yuan,
Joann Kalabathula,
Radosław P. Nowak,
Eric S. Fischer,
Nathanael S. Gray,
Priscilla L. Yang |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Portfolio
2019-08-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-019-11429-w
|
|---|